About GenScript
Founded in 2002, GenScript develops research tools and custom services for molecular biology, protein science and drug discovery. Its expertise spans gene synthesis, oligonucleotide production, peptide synthesis, recombinant protein expression and antibody development. The company combines synthetic biology, protein engineering and genome editing capabilities to support research from target identification through preclinical evaluation. Its platforms enable researchers to design DNA constructs, generate expression-ready clones, produce recombinant biomolecules and evaluate biological function. These capabilities support applications in cell and gene therapy, immunology, oncology, infectious disease research, synthetic biology and therapeutic development.
GenScript offers gene synthesis, cloning, plasmid DNA preparation, CRISPR reagents, peptides, recombinant proteins and antibody development services. Proprietary technologies including the GenTitan™ gene synthesis platform and TurboCHO™ expression system support efficient construct generation and recombinant protein production. The company also provides antibody discovery capabilities through its MonoRab™ platform, alongside molecular biology enzymes marketed under the Bestzyme® brand. Its Gene-to-Protein capabilities help streamline molecular biology and biologics research workflows, while its molecular cloning and expression platforms support functional studies, screening and assay development.
Europa Biosite’s subsidiaries distribute for Genscript in Denmark, Estonia, Finland, Germany, Iceland, Ireland, Latvia, Lithuania, Norway, Sweden and the United Kingdom.